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INTRODUCTION

This special issue on “Computer Methods and Programs in Biomedicine” is a collection of related papers selected and extended from those presented at the triennial IFAC Biological and Medical Systems (BMS 2012) Symposium in Budapest, Hungary during August 29-31, 2012.  

IFAC was founded in September 1957 and is a worldwide multinational federation of National Member Organisations (NMOs). Each NMO represents the engineering and scientific societies concerned with dynamic systems and control within its own country. The aims of the Federation are to promote the science and technology, both theory and application, of systems, signal and control in the broadest sense in all systems, whether, for example, biological, medical, engineering, physical, social or economic. 

Technical excellence is a main concern of IFAC. In a world where rapid and widespread dissemination of information has become possible for everybody, maintaining the highest level of scientific excellence is the only way in which an organisation like IFAC can prosper. Thus, IFAC prides itself on promoting consistent and rigorous peer review in all its publications.

The IFAC BMS 2012 Symposium is sponsored by the IFAC Technical Committee on Biological and Medical Systems (TC 8.2). There were 109 articles from 21 countries of which approximately 50% were part of invited sessions across a range of topics. Each paper had a minimum of 2 reviewers and the top 14 articles by reviewer grade were selected for this special edition, where the revised articles underwent a further rigorous independent peer-review. From this group of 14 and the journal’s review process 10 were accepted for this special edition. Taken together, we believe these selected articles constitute a valuable source of information on the broad state of the art in Biomedical Systems Modelling, Signal Processing and Control.






The first article by Evans and colleagues describes the modelling of tumour growth in xenografts animal models used in drug development. Xenograft animal models are a first line test in oncology studies for developing new drugs. However, the simple measurement of tumour growth over time in these simple models often masks several potentially important pathophysiological and biological changes that would help investigate the mode of drug action. This article presents a first model of tumour growth including histological biomarkers, and is designed to be structurally identifiable given the data available in such studies. Clinical data from a first use are then used to validate the model and approach. However, the overall paper presents a unique approach to model development for a targeted, and critical, clinical research outcome.

The next article by Hall and colleagues presents a mathematical model for the pharmacokinetics of the commonly used anti-malarial drug, artesunate. The research develops a series of constraints to enable the model to be identified, as it is not structurally identifiable with typical data. These constraints thus alter the model and these impacts are analysed and shown to still capture the observed dynamics. Hence, this article presents a new approach to adding insight via modelling assumptions, a key element of any model representation, to help address the significant and growing problem presented by malaria and our difficulty in treating it.

Keir and colleagues present a two compartment model to capture the dynamics of myoglobin in patients undergoing dialysis. The model is developed from data for a specific group of patients based on ensuring structural identifiability of the resulting model given the data that would be available. The model is validated predictively by its ability to capture observed data, and presents a further improvement in using structured model development methods to apply engineering principles to improving care, using models, in core therapeutic arenas.

Finally, Pretty and colleagues use a similar approach to creating and identifying an insulin kinetics model from newly emerging micro-dialysis data. This approach uses very rarely obtained data to develop and validate kinetics parameters for a well-known kinetics model that are not otherwise identifiable with typical data. It also assesses their validity by their ability to capture observed clinical data dynamics, and in relation to a range of prior insulin kinetics models that have all tried to address this problem.

From the area of model development, and particularly model development with a focus on ensuring identifiability of parameters for typically available data, there is a natural lead-in towards methods of system identification, identifiability analyses and the effect of sensor noise or timing on identified parameters.

System Identification and Identifiability:

Yu and colleagues present a novel identification method for a biomechanics problem. In particular, they parameterise a two muscle arm model incorporating a Hill muscle model so that it is identifiable. The method uses a mix of directly measure anthropomorphic data and inferred values to identify an equivalent mechanics model. The method is validated comparing measured and identified model results, and an error sensitivity analysis is presented that shows reduced error and sensitivity resulting from the assumptions that have to be made around body segment geometry in these models. 

Grandjean and colleagues then examine the application of four different methods to determine the structural identifiability and indistinguishability of parameters for a series of candidate nonlinear pharmacokinetic models used to capture the hepatic uptake of a therapeutic agent. The methods are analysed and validated using in vitro data. Structural identifiability analysis shows that, in this case, all candidate models were structurally distinguishable given the typical observations. The overall results present a clearly template for analysing and comparing models and the resulting identified parameters. 

Next, Docherty and colleagues assess the impact on parameter identification of the quality of the simulation method involved. Thus, given a model and data, errors after identification are often ascribed to the model or quality of data. However, this research shows that the simulation methods used in parameter identification and optimisation can also have a significant impact in certain cases. In particular, they point out that models with discrete step changes, such as are often found in lung recruitment models, can yield significant errors if the user is not very careful using otherwise well-accepted approaches to system identification.

Finally, Pretty and colleagues assess the impact of sensor errors and sensor measurement timing errors on identified parameters for insulin sensitivity in a well-known, structurally identifiable model. This article uses a range of observed and recorded sensor error models and a timing error model based on clinical observations of the pharmacodynamic glucose-insulin model in clinical use for decision support. Insulin sensitivity is the driving parameter in determining insulin dosing decisions. Overall it is found that the impact of reasonable sensor and timing errors can be notable, but are not likely to outweigh far larger variations in patient behaviour for the critically ill cohort examined. Thus, while these effects are overshadowed by physiological effects in the critically ill, their size may be more significant in use with ambulatory populations and in assessing hour-to-hour insulin sensitivity variability. The overall work thus links the impact of methods and errors in identification to potential impacts on model-based decision support.





Nogueira and colleagues present a nonlinear positive control law, for reference tracking in multi-input, single output positive systems, which is applied to an existing model and problem in depth of anaesthesia. Anaesthesia is a well-known area where model-based and automatic control has made great headway over the recent decade. The methods presented are shown to provide good potential control and provides a novel approach to visualising and designing control for this clinical scenario.
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